发明名称 | Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth | ||
摘要 | Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution in the heavy chain at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4 and an amino acid substitution in the light chain, these antibodies having improved potency and breadth. | ||
申请公布号 | US9493549(B2) | 申请公布日期 | 2016.11.15 |
申请号 | US201213714398 | 申请日期 | 2012.12.13 |
申请人 | THE ROCKEFELLER UNIVERSITY;CALIFORNIA INSTITUTE OF TECHNOLOGY | 发明人 | Diskin Ron;Bjorkman Pamela J.;Nussenzweig Michel;Scheid Johannes |
分类号 | C07K16/10 | 主分类号 | C07K16/10 |
代理机构 | Lewis Roca Rothgerber Christie LLP | 代理人 | Lewis Roca Rothgerber Christie LLP |
主权项 | 1. A human anti-CD4 binding site (anti-CD4bs) antibody having a heavy chain and a light chain, the heavy chain comprising a substitution at position 54 according to Kabat numbering, the substitution being selected from the group consisting of alanine, isoleucine, leucine, methionine, phenylalanine, tryptophan, tyrosine, valine, histidine, arginine, glutamine, asparagine, lysine, glutamic acid, and aspartic acid, the heavy chain comprising a sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 45, and 46; and the light chain comprising a sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, and 43. | ||
地址 | New York NY US |